These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26667234)

  • 1. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
    Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
    Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
    Hagio K; Amano T; Hayashi H; Takeshita T; Oshino T; Kikuchi J; Ohhara Y; Yabe I; Kinoshita I; Nishihara H; Yamashita H
    Sci Rep; 2021 Apr; 11(1):8109. PubMed ID: 33854152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.
    Page K; Guttery DS; Fernandez-Garcia D; Hills A; Hastings RK; Luo J; Goddard K; Shahin V; Woodley-Barker L; Rosales BM; Coombes RC; Stebbing J; Shaw JA
    Clin Chem; 2017 Feb; 63(2):532-541. PubMed ID: 27940449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    Yang X; Zhang K; Zhang C; Peng R; Sun C
    BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
    Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
    J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
    Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF
    Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.
    Frenel JS; Carreira S; Goodall J; Roda D; Perez-Lopez R; Tunariu N; Riisnaes R; Miranda S; Figueiredo I; Nava-Rodrigues D; Smith A; Leux C; Garcia-Murillas I; Ferraldeschi R; Lorente D; Mateo J; Ong M; Yap TA; Banerji U; Gasi Tandefelt D; Turner N; Attard G; de Bono JS
    Clin Cancer Res; 2015 Oct; 21(20):4586-96. PubMed ID: 26085511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
    Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
    Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
    Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Banks KC; Lanman RB; Talasaz A; Parker BA; Kurzrock R
    Oncotarget; 2016 Mar; 7(9):9707-17. PubMed ID: 26848768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients.
    Oltmann J; Heselmeyer-Haddad K; Hernandez LS; Meyer R; Torres I; Hu Y; Doberstein N; Killian JK; Petersen D; Zhu YJ; Edelman DC; Meltzer PS; Schwartz R; Gertz EM; Schäffer AA; Auer G; Habermann JK; Ried T
    Genes Chromosomes Cancer; 2018 Apr; 57(4):165-175. PubMed ID: 29181861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
    De Mattos-Arruda L; Weigelt B; Cortes J; Won HH; Ng CKY; Nuciforo P; Bidard FC; Aura C; Saura C; Peg V; Piscuoglio S; Oliveira M; Smolders Y; Patel P; Norton L; Tabernero J; Berger MF; Seoane J; Reis-Filho JS
    Ann Oncol; 2014 Sep; 25(9):1729-1735. PubMed ID: 25009010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast.
    Gruel N; Benhamo V; Bhalshankar J; Popova T; Fréneaux P; Arnould L; Mariani O; Stern MH; Raynal V; Sastre-Garau X; Rouzier R; Delattre O; Vincent-Salomon A
    Breast Cancer Res; 2014 May; 16(3):R46. PubMed ID: 24887297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis.
    Lu Q; Wei L; Cai S; Zhang Z; Zhang L
    Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):200-206. PubMed ID: 38015519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.
    Gonzalez-Angulo AM; Chen H; Karuturi MS; Chavez-MacGregor M; Tsavachidis S; Meric-Bernstam F; Do KA; Hortobagyi GN; Thompson PA; Mills GB; Bondy ML; Blumenschein GR
    Cancer; 2013 Jan; 119(1):7-15. PubMed ID: 22736407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
    Keup C; Benyaa K; Hauch S; Sprenger-Haussels M; Tewes M; Mach P; Bittner AK; Kimmig R; Hahn P; Kasimir-Bauer S
    Cell Mol Life Sci; 2020 Feb; 77(3):497-509. PubMed ID: 31254045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
    Santarpia L; Bottai G; Kelly CM; Győrffy B; Székely B; Pusztai L
    Oncologist; 2016 Sep; 21(9):1063-78. PubMed ID: 27384237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53.
    Ghaleb A; Yallowitz A; Marchenko N
    Commun Biol; 2019; 2():436. PubMed ID: 31799437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular alterations and prognosis of breast cancer with cutaneous metastasis.
    Xu Y; Ding L; Li C; Hua B; Wang S; Zhang J; Liu C; Guo R; Zhang Y
    Diagn Pathol; 2024 Jul; 19(1):93. PubMed ID: 38970069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.